Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin α v β 3-positive tumors: A first-in-human study.

Acta Pharm Sin B · 2025 · PMC11959955 · PMID 40177543

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

There were highly significant correlations between the 68 Ga-DOTA-3PRGD2 distribution on PET/CT and the 177 Lu-AB-3PRGD2 distribution on SPECT/CT.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Safety, pharmacokinetics, and dosimetry of &lt;sup&gt;177&lt;/sup&gt;Lu-AB-3PRGD2 in patients with advanced integrin &lt;i&gt;α&lt;/i&gt; &lt;sub&gt;v&lt;/sub&gt; &lt;i&gt;β&lt;/i&gt; &lt;sub&gt;3&lt;/sub&gt;-positive tumors: A first-in-human study.

The sentences

Safety, pharmacokinetics, and dosimetry of <sup>177</sup>Lu-AB-3PRGD2 in patients with advanced integrin <i>α</i> <sub>v</sub> <i>β</i> <sub>3</sub>-positive tumors: A first-in-human study.